Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease : Official journal of the American College of Gastroenterology | ACG

Secondary Logo

Journal Logo

Advanced Search
BRIEF COMMUNICATION

Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease

Botwin, Gregory J. BS1,2; Li, Dalin PhD1,2; Figueiredo, Jane PhD2,3; Cheng, Susan MD, MMSc, MPH4; Braun, Jonathan MD, PhD1,2,5; McGovern, Dermot P. B. MD, PhD1,2,5; Melmed, Gil Y. MD, MS, FACG, AGAF1,2

Author Information

1Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Los Angeles, California, USA;

2Department of Medicine, Cedars-Sinai, Los Angeles, California, USA;

3Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, USA;

4Department of Cardiology, Smidt Heart Institute, Cedars-Sinai, Los Angeles, California, USA;

5Department of Biomedical Sciences, Cedars-Sinai, Los Angeles, California, USA.

Correspondence: Gil Y. Melmed, MD, MS, FACG, AGAF. E-mail: [email protected].

The American Journal of Gastroenterology 116(8):p 1746-1751, August 2021. | DOI: 10.14309/ajg.0000000000001342

Abstract

INTRODUCTION: 

Patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from severe acute respiratory syndrome coronavirus-2 messenger RNA vaccine trials.

METHODS: 

We evaluated adverse events (AE) after messenger RNA vaccination in 246 adults with IBD participating in a longitudinal vaccine registry.

RESULTS: 

In general, AE frequency was similar to that reported in the general population. AEs were more common among younger patients and those with previous COVID-19. AEs were less common in individuals receiving advanced therapies with biologics or small-molecule inhibitors.

DISCUSSION: 

Those with IBD and other immune-mediated inflammatory diseases can be reassured that the AE risk is likely not increased, and may be reduced, while on advanced therapies.

© 2021 by The American College of Gastroenterology

Full Text Access for Subscribers:

Log In Here
ACG Member Access
Log In Here

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid